Valuation: Glaukos Corporation

Market Cap 9.83B 8.54B 7.95B 7.3B 13.79B 938B 14B 93.75B 36.79B 467B 36.91B 36.1B 1,566B P/E 2026 *
-206x
P/E 2027 * 568x
Enterprise Value 9.65B 8.39B 7.81B 7.17B 13.54B 922B 13.75B 92.08B 36.14B 459B 36.26B 35.46B 1,538B EV / Sales 2026 *
14x
EV / Sales 2027 * 11.4x
Free-Float
96.35%
Yield 2026 *
-
Yield 2027 * -
1 day-1.07%
1 week+8.56%
1 month+12.39%
3 months+18.90%
6 months+41.93%
Current year+47.66%
1 week 145.78
Extreme 145.7759
184
1 month 143.11
Extreme 143.11
184
Current year 93.96
Extreme 93.96
184
1 year 73.16
Extreme 73.16
184
3 years 59.22
Extreme 59.22
184
5 years 33.33
Extreme 33.33
184
10 years 23.08
Extreme 23.075
184
Manager TitleAgeSince
Chief Executive Officer 65 31/12/2000
Director of Finance/CFO 56 31/03/2022
President 50 31/03/2022
Director TitleAgeSince
Chairman 65 30/12/2021
Director/Board Member 71 30/06/2014
Director/Board Member 57 30/06/2014
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Fiscal year

Chief Financial Officer

30,000 0.0523%
09/07/26 Fiscal year

Chief Financial Officer

30,000 0.0523%
06/07/26 Fiscal year

Chief Financial Officer

30,000 0.0523%
Change 5-day change 1-year change 3-year change Capi.($)
-1.07%+8.56%+93.50%+123.13% 9.83B
-6.42%-1.38%-13.79%+18.62% 125B
-2.48%+1.62%+0.17%+0.61% 13.12B
+1.11%+10.55%-40.93%-65.72% 4.86B
-2.28%-0.67%-3.31%+36.23% 2.61B
-0.51%+7.84%+13.25%-53.59% 1.68B
+1.24%+5.88%-24.84%-30.57% 1.68B
+0.60%+5.00%-14.81%-19.58% 1.67B
+0.38%+2.07%-60.18%-81.93% 1.45B
Average -1.05%+2.94%-5.66%-8.09% 17.98B
Weighted average by Cap. -5.21%-0.16%-7.05%+18.71%

Financials

2026 *2027 *
Net sales 691M 600M 559M 513M 969M 65.93B 984M 6.59B 2.59B 32.83B 2.59B 2.54B 110B 842M 732M 681M 625M 1.18B 80.37B 1.2B 8.03B 3.15B 40.01B 3.16B 3.09B 134B
Net income -51.88M -45.1M -41.98M -38.54M -72.78M -4.95B -73.91M -495M -194M -2.47B -195M -191M -8.27B 18.93M 16.45M 15.31M 14.06M 26.55M 1.81B 26.96M 181M 70.84M 899M 71.08M 69.52M 3.02B
Net Debt -175M -152M -142M -130M -245M -16.69B -249M -1.67B -655M -8.31B -657M -642M -27.87B -273M -237M -221M -203M -383M -26.04B -389M -2.6B -1.02B -12.97B -1.02B -1B -43.48B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
31/07/26 US$166.72 -1.07% 1,032,220
30/07/26 US$168.52 +4.24% 2,559,596
29/07/26 US$161.66 +6.83% 3,137,806
28/07/26 US$151.33 -0.38% 1,144,674
27/07/26 US$151.91 -1.09% 727,532
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
166.72USD
Average target price
193.62USD
Spread / Average Target
+16.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock